Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer
- PMID: 1648142
- DOI: 10.1093/jnci/83.12.855
Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer
Abstract
Between April 1985 and May 1988, we conducted a randomized study comparing two standard chemotherapy regimens with the same regimens given on an alternating basis in patients with small-cell lung cancer. The patients were randomly assigned to receive cyclophosphamide at a dose of 800 mg/m2 intravenously (IV) on day 1, doxorubicin at 50 mg/m2 IV on day 1, and vincristine at 1.4 mg/m2 IV on day 1 (CAV); cisplatin at 80 mg/m2 IV on day 1 and etoposide at 100 mg/m2 IV on days 1, 3, and 5 (PE); or CAV alternating with PE (CAV/PE). Each regimen was repeated every 3-4 weeks. Three hundred patients were entered in the study, and 288 of them were eligible for analysis (97 for CAV, 97 for PE, and 94 for CAV/PE). The response rates for PE (78%) and CAV/PE (76%) were significantly higher than the rate for CAV (55%), while the complete response rates were similar (14%, 16%, and 15%, respectively). Nine (23%) of 39 patients who failed to respond to the initial CAV regimen responded to PE when they were crossed over. In contrast, only one (8%) of 13 patients responded to CAV after failing to respond to the PE regimen, suggesting that these two regimens were partially non-cross-resistant. The response duration on CAV/PE was significantly longer than that with CAV (P = .004). The survival time with CAV/PE (11.8 months) was superior to that with CAV (9.9 months) (P = .027) or that with PE (9.9 months) (P = .056). In patients with limited disease, the survival in the alternating arm was significantly superior to the survival in the CAV arm (P = .014) or the survival in the PE arm (P = .023). The toxic effects were acceptable in all three chemotherapy regimens. These results favor the alternating chemotherapy over either standard chemotherapy, such as CAV and PE, although the differences are not dramatic.
Similar articles
-
Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.J Clin Oncol. 1989 Apr;7(4):450-6. doi: 10.1200/JCO.1989.7.4.450. J Clin Oncol. 1989. PMID: 2538577 Clinical Trial.
-
Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group.J Clin Oncol. 1998 Jun;16(6):2126-32. doi: 10.1200/JCO.1998.16.6.2126. J Clin Oncol. 1998. PMID: 9626212 Clinical Trial.
-
Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors?Oncol Rep. 2000 Mar-Apr;7(2):305-10. Oncol Rep. 2000. PMID: 10671676 Clinical Trial.
-
The use of VP-16 plus cisplatin during induction chemotherapy for small-cell lung cancer.Semin Oncol. 1986 Sep;13(3 Suppl 3):10-6. Semin Oncol. 1986. PMID: 3020692 Review.
-
[Chemotherapy of small cell lung cancer].Gan To Kagaku Ryoho. 1996 Aug;23(9):1116-23. Gan To Kagaku Ryoho. 1996. PMID: 8751797 Review. Japanese.
Cited by
-
The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study.Cancer Res Treat. 2024 Apr;56(2):422-429. doi: 10.4143/crt.2023.913. Epub 2023 Oct 23. Cancer Res Treat. 2024. PMID: 37871898 Free PMC article.
-
Small-Cell Lung Cancer-An Update on Targeted and Immunotherapies.Int J Mol Sci. 2023 May 1;24(9):8129. doi: 10.3390/ijms24098129. Int J Mol Sci. 2023. PMID: 37175833 Free PMC article. Review.
-
Primary tracheal small-cell carcinoma detected 11 months after surgery for pulmonary large-cell neuroendocrine carcinoma: A case report.Thorac Cancer. 2023 May;14(13):1212-1216. doi: 10.1111/1759-7714.14860. Epub 2023 Mar 28. Thorac Cancer. 2023. PMID: 36977572 Free PMC article.
-
Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study.Cancers (Basel). 2023 Feb 28;15(5):1543. doi: 10.3390/cancers15051543. Cancers (Basel). 2023. PMID: 36900334 Free PMC article.
-
[Small cell lung cancer-Established standards and new approaches].Inn Med (Heidelb). 2022 Jul;63(7):724-730. doi: 10.1007/s00108-022-01362-4. Epub 2022 Jun 27. Inn Med (Heidelb). 2022. PMID: 35925272 Review. German.
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous